程序性死亡受体1抑制剂治疗甲状腺癌的研究进展

doi:10.3760/cma.j.issn.1007-1245.2023.11.001

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (11): 1481-1485.DOI: 10.3760/cma.j.issn.1007-1245.2023.11.001

• 医学新进展 • 下一篇

程序性死亡受体1抑制剂治疗甲状腺癌的研究进展

王艺霏薛海波

滨州医学院附属医院内分泌科，滨州　256603

收稿日期:2023-01-30 出版日期:2023-06-01 发布日期:2023-06-25
通讯作者: 薛海波，Email：xuehaibo@sina.com
基金资助:
山东省自然科学基金（ZR2022MH175）；山东省研究生教育创新计划项目（20038612）；滨州医学院附属医院科研创新团队项目（202031）；滨州医学院附属医院后备领军人才项目（JC2019-03）

Research progress of programmed cell death-1 inhibitors in the treatment of thyroid carcinoma

Wang Yifei, Xue Haibo

Department of Endocinology, Binzhou Medical University Hospital, Binzhou 256603, China

Received:2023-01-30 Online:2023-06-01 Published:2023-06-25
Contact: Xue Haibo, Email: xuehaibo@sina.com
Supported by:
Natural Science Foundation of Shandong Province (ZR2022MH175); Innovation Program of Post-graduate Education of Shandong Province (20038612); Scientific Research and Innovation Team Project of Binzhou Medical University Hospital (202031); Reserve Leading Talents Project of Binzhou Medical University Hospital (JC2019-03)

摘要/Abstract

摘要：

程序性死亡受体1（programmed cell death 1，PD-1）/程序性死亡配体1（programmed cell death-ligand 1，PD-L1）是重要的免疫检查点，在抑制抗肿瘤免疫反应中起作用，参与肿瘤细胞免疫逃逸机制。PD-1/PD-L1抑制剂通过阻断活化的T细胞上的PD-1与表达PD-L1的肿瘤细胞结合，在非小细胞肺癌、晚期黑色素瘤、甲状腺癌等多种肿瘤治疗中取得了良好的治疗效果。本文主要对PD-1抑制剂在甲状腺癌治疗中的研究进展进行综述。

关键词:

甲状腺癌, 免疫检查点抑制剂, 程序性死亡受体1, 分子靶向治疗, 进展

Abstract:

Programmed cell death-1 (PD-1) / programmed cell death-ligand 1 (PD-L1) are important immune checkpoints, which play pivotal roles in suppressing anti-cancer immunity and are involved in immune escape mechanism of tumor cells. PD-1/PD-L1 inhibitors have achieved remarkable therapeutic effects in non-small-cell lung cancer, advanced melanoma, thyroid carcinoma, and other tumors by blocking the binding of PD-1 on activated T-cells to PD-L1 expressed on tumor cells. This paper mainly reviews the progress in PD-1 inhibitors in the treatment of thyroid carcinoma.

Key words:

Thyroid carcinoma, Immune checkpoint inhibitors, Programmed cell death-1, Molecular targeted therapy, Progress

王艺霏薛海波.

程序性死亡受体1抑制剂治疗甲状腺癌的研究进展 [J]. 国际医药卫生导报, 2023, 29(11): 1481-1485.

Wang Yifei, Xue Haibo.

Research progress of programmed cell death-1 inhibitors in the treatment of thyroid carcinoma [J]. International Medicine and Health Guidance News, 2023, 29(11): 1481-1485.

参考文献

[1] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J].CA Cancer J Clin,2021,71(1):7-33.DOI:10.3322/caac.21654.
[2] Cheng F, Xiao J, Shao C, et al. Burden of thyroid cancer from 1990 to 2019 and projections of incidence and mortality until 2039 in China: findings from global burden of disease study[J].Front Endocrinol (Lausanne),2021,12:738213.DOI:10.3389/fendo.2021.738213.
[3] Yang J, Barletta JA. Anaplastic thyroid carcinoma[J].Semin Diagn Pathol,2020,37(5):248-256.DOI:10.1053/j.semdp.2020.06.005.
[4] 郑传铭,王佳峰,吕恬,等. "中国肿瘤整合诊治指南(CACA)——甲状腺癌诊治指南"解读[J]. 肿瘤学杂志,2022,28(8):627-630.DOI:10.11735/j.issn.1671-170X.2022.08.B001.
[5] Antonelli A, Ferrari SM, Fallahi P. Current and future immunotherapies for thyroid cancer[J].Expert Rev Anticancer Ther,2018,18(2):149-159.DOI:10.1080/14737140.2018.1417845.
[6] Kwok G, Yau TC, Chiu JW, et al. Pembrolizumab (Keytruda)[J].Hum Vaccin Immunother,2016,12(11):2777-2789.DOI:10.1080/21645515.2016.1199310.
[7] Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production[J].J Immunol,2003,170(3):1257-1266.DOI:10.4049/jimmunol. 170.3. 1257.
[8] Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J].EMBO J,1992,11(11):3887-3895.DOI:10.1002/j.1460-2075.1992.tb05481.x.
[9] Dai S, Jia R, Zhang X, et al. The PD-1/PD-Ls pathway and autoimmune diseases[J].Cell Immunol,2014,290(1):72-79.DOI:10.1016/j.cellimm.2014.05.006.
[10] Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer[J].Clin Cancer Res,2013,19(5):1021-1034.DOI:10.1158/1078-0432.CCR-12-2063.
[11] Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity[J].Annu Rev Immunol,2008,26:677-704.DOI:10.1146/annurev.immunol.26.021607. 090331.
[12] Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion[J].Nat Med,2002,8(8):793-800.DOI:10.1038/nm730.
[13] Li Y, Liang Z, Tian Y, et al. High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2[J].Cancer Sci,2018,109(8):2435-2445.DOI:10.1111/cas.13666.
[14] Iwai Y, Hamanishi J, Chamoto K, et al. Cancer immunotherapies targeting the PD-1 signaling pathway[J].J Biomed Sci,2017,24(1):26.DOI:10.1186/s12929-017- 0329-9.
[15] Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway[J].N Engl J Med,2016,375(18):1767-1778.DOI:10.1056/NEJMra1514296.
[16] Ni L, Ma CJ, Zhang Y, et al. PD-1 modulates regulatory T cells and suppresses T-cell responses in HCV-associated lymphoma[J].Immunol Cell Biol,2011,89(4):535-539.DOI:10.1038/icb.2010.121.
[17] Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck[J].Oral Oncol,2014,50(7):627-632.DOI:10.1016/j.oraloncology.2014.04.003.
[18] Okazaki T, Chikuma S, Iwai Y, et al. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application[J].Nat Immunol,2013,14(12):1212-1218.DOI:10.1038/ni.2762.
[19] Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells[J].J Exp Med,2009,206(13):3015-3029.DOI:10.1084/jem.20090847.
[20] Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance[J].Cell,2008,133(5):775-787.DOI:10.1016/j.cell.2008.05.009.
[21] Azuma T, Yao S, Zhu G, et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells[J].Blood,2008,111(7):3635-3643.DOI:10.1182/blood-2007-11-123141.
[22] Park JJ, Omiya R, Matsumura Y, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance[J].Blood,2010,116(8):1291-1298.DOI:10.1182/blood-2010-01-265975.
[23] Mehnert JM, Varga A, Brose MS, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer[J].BMC Cancer,2019,19(1):196.DOI:10.1186/s12885-019-5380-3.
[24] Hatashima A, Archambeau B, Armbruster H, et al. An evaluation of clinical efficacy of immune checkpoint inhibitors for patients with anaplastic thyroid carcinoma[J].Thyroid,2022,32(8):926-936.DOI:10.1089/thy.2022.0073.
[25] Naing A, Gainor JF, Gelderblom H, et al. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors[J].J Immunother Cancer,2020,8(1):e000530.DOI:10.1136/jitc-2020-000530.
[26] Capdevila J, Wirth LJ, Ernst T, et al. PD-1 blockade in anaplastic thyroid carcinoma[J]. Journal of clinical oncology,2020,38(23):2620-2627.DOI:10.1200/JCO.19.02727.
[27] Danysh BP, Rieger EY, Sinha DK, et al. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model[J].Oncotarget,2016,7(21):30907-30923.DOI:10.18632/oncotarget.9023.
[28] Brauner E, Gunda V, Vanden Borre P, et al. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer[J].Oncotarget,2016,7(13):17194-17211.DOI:10.18632/oncotarget.7839.
[29] Iyer PC, Dadu R, Gule-Monroe M, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma[J].J Immunother Cancer,2018,6(1):68.DOI:10.1186/s40425- 018-0378-y.
[30] Dierks C, Seufert J, Aumann K, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma[J].Thyroid,2021,31(7):1076-1085.DOI:10.1089/thy.2020.0322.
[31] 赵柳燕,宋守君,薛海波. 分子靶向药物治疗难治性甲状腺癌的疗效及安全性的meta分析[J]. 国际医药卫生导报,2022,28(17):2369-2376.DOI:10.3760/cma.j.issn.1007- 1245.2022.17.001.

程序性死亡受体1抑制剂治疗甲状腺癌的研究进展

Research progress of programmed cell death-1 inhibitors in the treatment of thyroid carcinoma

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	刘玉姣王超刘菲. 中西医结合治疗产后盆底肌筋膜疼痛的研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1204-1207.
[2]	柯金王恒石张善兰. 卡瑞利珠单抗免疫相关不良反应临床分析 [J]. 国际医药卫生导报, 2023, 29(9): 1258-1262.
[3]	王泽川黄月琴. 急性髓系白血病靶向药物治疗新进展 [J]. 国际医药卫生导报, 2023, 29(8): 1045-1048.
[4]	徐仕杰罗泽斌陈晓东. CT肺动脉成像在肺栓塞诊治中的应用进展 [J]. 国际医药卫生导报, 2023, 29(8): 1053-1056.
[5]	张衡潘广涛殷鸣张平尹霞. 自体脂肪移植在整形外科中的研究进展 [J]. 国际医药卫生导报, 2023, 29(7): 889-892.
[6]	吴雪梅张玉杰解胜华. 银屑病与心血管共病关系的研究进展 [J]. 国际医药卫生导报, 2023, 29(4): 453-456.
[7]	袁晓莉王振波. 食管鳞癌的肿瘤免疫微环境和免疫检查点抑制剂研究进展 [J]. 国际医药卫生导报, 2023, 29(3): 310-314.
[8]	杨丽娜王玉夏铂. 烙灸临床应用研究进展 [J]. 国际医药卫生导报, 2023, 29(2): 154-.
[9]	汪小桐戴碗琴. 细菌整合子-基因盒系统表达调控的研究进展 [J]. 国际医药卫生导报, 2023, 29(12): 1636-1639.
[10]	周兆年郑伟强. 血小板在肝硬化中的研究进展 [J]. 国际医药卫生导报, 2023, 29(12): 1640-1643.
[11]	孙悦龚荣花. 肾上腺素生理盐水冲洗液在改善关节镜手术视野中的研究进展 [J]. 国际医药卫生导报, 2023, 29(11): 1485-1488.
[12]	昝兴淳许季详周小妹. 高压氧舱内康复治疗的临床应用研究进展及其可行性分析 [J]. 国际医药卫生导报, 2023, 29(11): 1489-1493.
[13]	张善兰刘晓辉柯金王恒石肖素芳. 度伐利尤单抗致Graves眼病1例 [J]. 国际医药卫生导报, 2023, 29(11): 1583-1584.
[14]	林璟珊, 汤诗恒, 王乙洋, 李玉霞. 脑卒中患者功能锻炼依从性的研究进展[J]. 国际医药卫生导报, 2022, 28(9): 1251-1256.
[15]	蒙永晖. 骨质疏松性脊柱骨折的研究进展[J]. 国际医药卫生导报, 2022, 28(9): 1330-1332.